About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT03655691

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Lead sponsor: Eirion Therapeutics Inc.•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Eirion Therapeutics Inc.

This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.

Age

25 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•25 - 65 years of age
•minimal to moderate Crow's Feet wrinkles at rest
•moderate to severe Crow's Feet wrinkles on contraction
•willingness to refrain from any product affecting skin remodeling
•female subjects must be not pregnant and non-lactating

Exclusion Criteria

•history of adverse reactions to any prior botulinum toxin treatments
•history of vaccination or non-response to any prior botulinum toxin treatments
•botulinum toxin treatment in the prior 6 months
•present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
•history of peri-ocular surgery, brow lift or related procedures
•procedures affecting the lateral canthal region in the prior 12 months
•application of topical prescription medication to the treatment area
•female subjects who are pregnant or are nursing a child

Related studies

RECRUITINGPhase 1/2

A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet

NCT04818203 · Crow's Feet

COMPLETEDPhase 2

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916 · Lateral Canthal Lines, LCL, Crow's Feet

COMPLETEDPhase 3

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT04157686 · Glabellar Lines, Lateral Canthal Lines

Not Yet RecruitingNA

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

NCT06402058 · Crow's Feet Lines

To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet

NCT06376838 · Crow's Feet Lines

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 21, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment79

Start dateAug 2018

Last updatedApr 21, 2022

Condition

Lateral Canthal Lines Crow's Feet

Locations shown

Baumann Cosmetic & Research Institute

Miami, Florida

Radiant Research, Inc.

Pinellas Park, Florida

Research Institute of the Southeast, LLC

West Palm Beach, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2022Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions